Lexicon Pharmaceuticals, INC.
Forward trial catalysts linked to LXRX
CSA tracks 1 forward catalyst for Lexicon Pharmaceuticals, INC. across 1 asset, spanning Phase 3. The nearest is a readout expected Jan 2027 (month precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Diabetic Nephropathies, Obstructive Cardiomyopathy, Hypertrophic.
LXRX in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Lexicon Pharmaceuticals, INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
2 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| sotagliflozin | NCT06481891 catalyst | Phase 3 | Active, not recruiting | 2027-01 | Experimental | Lexicon Pharmaceuticals | Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy |
| sotagliflozin | NCT06217302 | Phase 3 | Recruiting | 2028-12 | Active comparator | Alessandro Doria | Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure |
Every trial the CSA sample links to LXRX's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →